AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15067698 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated beads
Number of subjects: 0
Study 15067698 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass thermoplastic system
Number of subjects: 0
Study 15067698 — intervention group
Group type: COMPARATOR
Intervention: Unmanipulated drug
Number of subjects: 0
Study 11144994 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.5 mg as an intravenous (i.v.) infusion over 15 minutes
Number of subjects: 10
Study 11144994 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.5 mg as an intramuscular (i.m.) injection
Number of subjects: 10
Study 11144994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10096255 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 0
Study 10096255 — intervention group
Group type: COMPARATOR
Intervention: Seville orange juice
Number of subjects: 0
Study 10096255 — intervention group
Group type: EXPERIMENTAL
Intervention: 6',7'-Dihydroxybergamottin
Number of subjects: 0
Study 7704983 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study 7704983 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0
Study 7704983 — intervention group
Group type: COMPARATOR
Intervention: Tissue plasminogen activator (TPA)
Number of subjects: 0
Study 7704983 — intervention group
Group type: COMPARATOR
Intervention: All trials
Number of subjects: 0
Study 2280242 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic hypoglycaemia
Number of subjects: 66
Study 2280242 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical hypoglycaemia
Number of subjects: 66
Study 2280242 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic episodes
Number of subjects: 66
Study 2280242 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical episodes
Number of subjects: 66
Study 6448620 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (large doses)
Number of subjects: 9
Study 6448620 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (conventional doses)
Number of subjects: 9
Study 29458401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ding-Kun-Dan (DKD) pre-treatment for 3 months before IVF/ICSI
Number of subjects: 278
Study 27197829 — intervention group
Group type: EXPERIMENTAL
Intervention: NGT decompression (NGT group; n=108)
Number of subjects: 210
Study 27197829 — intervention group
Group type: COMPARATOR
Intervention: No NGT decompression (no-NGT group; n=102)
Number of subjects: 210
Study 24602082 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 0.25 W
Number of subjects: 20
Study 24602082 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 0.5 W
Number of subjects: 20
Study 24602082 — intervention group
Group type: COMPARATOR
Intervention: Control group (same laser applied without laser emission)
Number of subjects: 20
Study 22738299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 15
Study 20088810 — intervention group
Group type: EXPERIMENTAL
Intervention: 900mg/d algal DHA
Number of subjects: 485
Study 17550787 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine monotherapy (n=19)
Number of subjects: 41
Study 17550787 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine add-on therapy (n=22)
Number of subjects: 41
Study 15931573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterocarpus marsupium extract (PM extract) 450 mg
Number of subjects: 0
Study 15931573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterostilbene
Number of subjects: 0
Study 15931573 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 0
Study 15931573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterocarpus marsupium extract (PM extract)
Number of subjects: 0
Study 12929273 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg via a 15-minute infusion)
Number of subjects: 0
Study 12929273 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (90 mg via a two-hour infusion)
Number of subjects: 0
Study 10780795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 90
Study 10780795 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 90
Study 10780795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8842930 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrics-focused acute medicine inpatient rotation with a geriatrics-trained internist attending (n = 44)
Number of subjects: 93
Study 8842930 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrics-focused acute medicine inpatient rotation with a non-geriatrics-trained internist attending (n = 25)
Number of subjects: 93
Study 8842930 — intervention group
Group type: COMPARATOR
Intervention: No exposure to the intervention (n = 24)
Number of subjects: 93
Study 8842930 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 93
Study 1530836 — intervention group
Group type: COMPARATOR
Intervention: 40 micrograms ipratropium bromide
Number of subjects: 22
Study 1530836 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms fenoterol hydrobromide
Number of subjects: 22
Study 1530836 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 40 micrograms ipratropium and 100 micrograms fenoterol
Number of subjects: 22
Study 1530836 — intervention group
Group type: COMPARATOR
Intervention: Control (ipratropium)
Number of subjects: 22
Study 6238551 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg
Number of subjects: 80
Study 6238551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg
Number of subjects: 80
Study 6238551 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg and Cimetidine, 300 mg
Number of subjects: 80
Study 6238551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 3946851 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline (10 +/- 1 mg/kg, orally)
Number of subjects: 6
Study 3946851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30119704 — intervention group
Group type: EXPERIMENTAL
Intervention: Group singing intervention
Number of subjects: 54
Study 30119704 — intervention group
Group type: COMPARATOR
Intervention: Group creative play intervention
Number of subjects: 54
Study 26829597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine augmentation therapy at 100 mg/d for subjects not taking valproate and 75 mg/d for subjects taking valproate.
Number of subjects: 37
Study 26829597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine augmentation therapy (specific doses based on valproate use).
Number of subjects: 37
Study 24896237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycaemic index (GI) diet
Number of subjects: 372
Study 21912843 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Family Psychoeducational Psychotherapy (MF-PEP)
Number of subjects: 165
Study 20213456 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic VIH
Number of subjects: 146
Study 20213456 — intervention group
Group type: COMPARATOR
Intervention: Open VIH
Number of subjects: 146
Study 18564199 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin-noradrenalin reuptake inhibitor (SNRI)
Number of subjects: 684
Study 18564199 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 684
Study 18564199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study 18564199 — intervention group
Group type: EXPERIMENTAL
Intervention: Last observation carried forward (LOCF)
Number of subjects: 684
Study 18564199 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed case (OC)
Number of subjects: 684
Study 18564199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model for repeated measures (MMRM)
Number of subjects: 684
Study 15929820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 213
Study 15929820 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerin
Number of subjects: 213
Study 12802653 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal (TAPP) repair
Number of subjects: 120
Study 12802653 — intervention group
Group type: COMPARATOR
Intervention: Open mesh repair
Number of subjects: 120
Study 10763936 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-Fr Maloney dilator
Number of subjects: 23
Study 10763936 — intervention group
Group type: COMPARATOR
Intervention: 26-Fr Maloney dilator
Number of subjects: 23
Study 8625713 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education program (empirically based and culturally sensitive)
Number of subjects: 0
Study 8625713 — intervention group
Group type: COMPARATOR
Intervention: Control classes
Number of subjects: 0
Study 1604872 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) administered as a single daily dose
Number of subjects: 10
Study 1604872 — intervention group
Group type: COMPARATOR
Intervention: Divided doses of valproic acid (VPA) thrice daily
Number of subjects: 10
Study 2857803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 330 mg
Number of subjects: 240
Study 2857803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 75 mg and Aspirin 330 mg
Number of subjects: 240
Study 2857803 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 240
Study 30482552 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 μg.kg−1 with bupivacaine 0.165%
Number of subjects: 80
Study 30482552 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.165% alone
Number of subjects: 80
Study 30482552 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 μg.kg−1 with bupivacaine 0.165%
Number of subjects: 80
Study 30482552 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 μg.kg−1 with bupivacaine 0.165%
Number of subjects: 80
Study 30342902 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching (25% H2O2) followed by resin infiltration
Number of subjects: 27
Study 30342902 — intervention group
Group type: COMPARATOR
Intervention: Placebo bleaching (ACP gel) followed by resin infiltration
Number of subjects: 27
Study 30342902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BLI and NBLI) after resin infiltration
Number of subjects: 27
Study 30342902 — intervention group
Group type: EXPERIMENTAL
Intervention: BLI group after 3 months
Number of subjects: 27
Study 27050244 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 ml of 'BEET It Sport' nitrate shot containing 6.4 millimoles (mmol.L) or 400 mg of nitrate
Number of subjects: 12
Study 27050244 — intervention group
Group type: COMPARATOR
Intervention: Blackcurrant placebo drink
Number of subjects: 12
Study 24502856 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 45
Study 24502856 — intervention group
Group type: COMPARATOR
Intervention: Steel instruments
Number of subjects: 45
Study 22253394 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine therapy
Number of subjects: 1640
Study 22253394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1640
Study 20704115 — intervention group
Group type: COMPARATOR
Intervention: PFNA
Number of subjects: 80
Study 20704115 — intervention group
Group type: EXPERIMENTAL
Intervention: Targon PF
Number of subjects: 80
Study 17521311 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg daily for 2 weeks
Number of subjects: 483
Study 17521311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 16390760 — intervention group
Group type: EXPERIMENTAL
Intervention: HT + FA (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate daily and 5 mg folic acid/day)
Number of subjects: 40
Study 16390760 — intervention group
Group type: COMPARATOR
Intervention: HT + placebo (0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate daily)
Number of subjects: 40
Study 16390760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 12015519 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral 17beta‐estradiol (7.5 microg/24 h) delivered by a vaginal ring (Estring) for 12 months
Number of subjects: 60
Study 12015519 — intervention group
Group type: COMPARATOR
Intervention: No treatment for 12 months
Number of subjects: 60
Study 10725861 — intervention group
Group type: EXPERIMENTAL
Intervention: IDC-P subpattern A (trabecular)
Number of subjects: 26
Study 10725861 — intervention group
Group type: EXPERIMENTAL
Intervention: IDC-P subpattern B (cribriform)
Number of subjects: 26
Study 10725861 — intervention group
Group type: EXPERIMENTAL
Intervention: IDC-P subpattern C (solid/comedo)
Number of subjects: 26
Study 10725861 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic criteria for IDC-P
Number of subjects: 26
Study 10725861 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostains for prostate-specific antigen, MUC-2, androgen receptor, and Ki-67
Number of subjects: 26
Study 9148193 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-vision condition
Number of subjects: 0
Study 9148193 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-visual feedback condition
Number of subjects: 0
Study 9148193 — intervention group
Group type: EXPERIMENTAL
Intervention: No-vision 0 sec delay condition
Number of subjects: 0
Study 9148193 — intervention group
Group type: EXPERIMENTAL
Intervention: No-vision 5 sec delay condition
Number of subjects: 0
Study 9148193 — intervention group
Group type: COMPARATOR
Intervention: Control lines
Number of subjects: 0
Study 1623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg/day for one month)
Number of subjects: 14
Study 1623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reduction of clubbed fingertips
Number of subjects: 14
Study 1623678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6202678 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg subcutaneous disulfiram implant
Number of subjects: 120
Study 6202678 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg subcutaneous disulfiram implant
Number of subjects: 120
Study 6202678 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg subcutaneous disulfiram implant
Number of subjects: 120
Study 6202678 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 31046521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 40
Study 31046521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29755598 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-authorship (SA) only
Number of subjects: 62
Study 29755598 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-authorship with implementation intentions (SA+ii)
Number of subjects: 62
Study 29755598 — intervention group
Group type: COMPARATOR
Intervention: Active control (expert-authored messages)
Number of subjects: 62
Study 26990867 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oestriol cream for 6 weeks
Number of subjects: 68
Study 26258804 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (unsupervised session of at least 50 minutes, four times a week)
Number of subjects: 151
Study 26258804 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued physical activity as before)
Number of subjects: 151
Study 26258804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (physical activity)
Number of subjects: 151
Study 23136215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression devices (PCDs)
Number of subjects: 51
Study 23136215 — intervention group
Group type: COMPARATOR
Intervention: Control (no PCDs)
Number of subjects: 51
Study 21041063 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Children's Hand Skills (ACHS)
Number of subjects: 134
Study 18304883 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg
Number of subjects: 586
Study 18304883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 16931683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (60 mg)
Number of subjects: 10
Study 16931683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14560766 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile-dependent support vector regression (PD-SVR)
Number of subjects: 110
Study 14560766 — intervention group
Group type: COMPARATOR
Intervention: Classical multilayer perceptron (MLP)
Number of subjects: 110
Study 14560766 — intervention group
Group type: COMPARATOR
Intervention: Autoregressive Conditional Heteroskedasticity (ARCH) model
Number of subjects: 110
Study 10901475 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 242
Study 10901475 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 2% three times daily
Number of subjects: 242
Study 9488944 — intervention group
Group type: EXPERIMENTAL
Intervention: THP (20 mg dissolved in 40 ml saline or 5% dextrose, administered intravesically once a week for 10 weeks)
Number of subjects: 80
Study 9488944 — intervention group
Group type: COMPARATOR
Intervention: Control (40 ml saline administered intravesically once a week for 10 weeks)
Number of subjects: 80
Study 9488944 — intervention group
Group type: EXPERIMENTAL
Intervention: THP
Number of subjects: 80
Study 9488944 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 8405521 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen
Number of subjects: 15
Study 8405521 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen/10 mg progestin
Number of subjects: 15
Study 8405521 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg conjugated equine estrogen
Number of subjects: 15
Study 8405521 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15
Study 3769774 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder
Number of subjects: 311
Study 3769774 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call reminder
Number of subjects: 311
Study 3769774 — intervention group
Group type: COMPARATOR
Intervention: Monitoring for refill compliance only (Control)
Number of subjects: 311
Study 30349198 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 150 mg
Number of subjects: 40
Study 30349198 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 300 mg
Number of subjects: 40
Study 30349198 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 450 mg
Number of subjects: 40
Study 30349198 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 600 mg
Number of subjects: 40
Study 30349198 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 150-450 mg
Number of subjects: 40
Study 30349198 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1 150-600 mg
Number of subjects: 40
Study 27069169 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus Oxaliplatin (PO group)
Number of subjects: 169
Study 27069169 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin (OX group)
Number of subjects: 169
Study 24008819 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-1 intramuscular (IM) regimen (group A)
Number of subjects: 181
Study 24008819 — intervention group
Group type: COMPARATOR
Intervention: Essen regimen (group B)
Number of subjects: 181
Study 23872591 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins plus niacin (1500 mg daily)
Number of subjects: 145
Study 23872591 — intervention group
Group type: COMPARATOR
Intervention: Statins plus placebo
Number of subjects: 145
Study 21178911 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg hyperbaric bupivacaine plus 25 µg fentanyl
Number of subjects: 60
Study 21178911 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg hyperbaric levobupivacaine plus 25 µg fentanyl
Number of subjects: 60
Study 17143000 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroid treatment (SST)
Number of subjects: 30
Study 17143000 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid treatment (NST)
Number of subjects: 30
Study 17143000 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30
Study 17078095 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA
Number of subjects: 924
Study 17078095 — intervention group
Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 924
Study 17078095 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA and Gd‐DTPA
Number of subjects: 924
Study 12809171 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month intensive medical management
Number of subjects: 248
Study 12809171 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control achieved
Number of subjects: 248
Study 12809171 — intervention group
Group type: COMPARATOR
Intervention: Non-controlled subjects
Number of subjects: 248
Study 10969306 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 50 mg hyperbaric lidocaine, 5% (n = 10)
Number of subjects: 28
Study 10969306 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 28
Study 10969306 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 50 mg hyperbaric lidocaine, 5%
Number of subjects: 28
Study 10969306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8985547 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago photoscreener
Number of subjects: 113
Study 8985547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dortmans photoscreener
Number of subjects: 113
Study 7871905 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking 5-HT3 receptors with ondansetron or tropisetron-hydrochloride
Number of subjects: 0
Study 7871905 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3340422 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 micrograms/kg fentanyl (open and double-blind intravenous infusion)
Number of subjects: 116
Study 3340422 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple random staircase (MRS) assessment method
Number of subjects: 116